- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
March 26, 2024Ronald Schutz, Brendan Johnson Named to Forbes Top 200 Lawyers in the United States
-
March 21, 2024Robins Kaplan Firm Members Appointed to Law360 Editorial Boards
-
March 20, 2024Brandon Vaughn Inducted into The International Society of Barristers
-
April 5, 2024Mass Torts Made Perfect
-
April 17, 2024American Antitrust Institute Virtual CLE Lunch & Learn
-
May 2-3, 2024ACI Advanced Forum on Managed Care Disputes and Litigation
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
March 2024Do We Have to Share That Information? Attorney-Client Privilege in the Multi-Entity Context
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Federal district court cases that are filed pursuant to the Hatch-Waxman Act
Second Quarter
This chart summarizes the case name, presiding judge, drug, and patents-at-issue in all federal district court cases that are filed pursuant to the Hatch-Waxman Act. It also includes the same information for proceedings before the Patent Trial and Appeal Board concerning Orange Book-listed patents.
Case Name | Date Filed | Judge | Drug | Patent No(s). |
---|---|---|---|---|
Exeltis USA, Inc. v. Lupin Ltd., 22-0434 (D. Del.) | Apr. 1, 2022 | Honorable Richard G. Andrews | Slynd® (drospirenone tablets) | 9,603,860 10,179,140 10,603,281 10,849,857 10,987,364 11,123,299 |
Neurocrine Biosciences, Inc. v. Zydus Pharms. (USA) Inc., 22-0439 (D. Del.) | Apr. 1, 2022 | Honorable MaryEllen Noreika | Ingrezza® (valbenazine capsules) | 10,065,952 10,844,058 10,851,103 10,851,104 10,857,137 10,857,148 10,874,648 10,906,902 10,906,903 10,912,771 10,919,892 10,940,141 10,952,997 10,993,941 11,026,931 11,026,939 11,040,029 |
Novartis Pharms. Corp. v. Zydus Pharms. (USA) Inc., 22-0440 (D. Del.) | Apr. 1, 2022 | Honorable Richard G. Andrews | Entresto® (sacubitril / valsartan tablets) | 11,058,667 |
Azurity Pharms., Inc. v. CoreRx, Inc., 22- 0784 (M.D. Fla.) | Apr. 1, 2022 | Honorable Steven D. Merryday | Epaned® (enalapril maleate oral solution) | 11,040,023 11,141,405 |
Neurocrine Biosciences, Inc. v. Zydus Pharms. (USA) Inc., 22-1882 (D.N.J.) | Apr. 1, 2022 | Honorable Christine P. O'Hearn | Ingrezza® (valbenazine capsules) | 10,065,952 10,844,058 10,851,103 10,851,104 10,857,137 10,857,148 10,874,648 10,906,902 10,906,903 10,912,771 10,919,892 10,940,141 10,952,997 10,993,941 11,026,931 11,026,939 11,040,029 |
Merck Sharp & Dohme Corp. v. Mankind Pharma Ltd., 22-0444 (D. Del.) | Apr. 4, 2022 | Honorable Richard G. Andrews | Januvia® (sitagliptin phosphate tablets) | 7,326,708 |
Celgene Corp. v. MSN Labs. Private Ltd., 22- 1993 (D.N.J.) | Apr. 6, 2022 | Honorable Esther Salas | Pomalyst® (pomalidomide capsules) | 8,198,262 8,673,939 8,735,428 8,828,427 9,993,467 10,555,939 |
Evoke Pharma, Inc. v. Teva Pharms., Inc., 22- 2019 (D.N.J.) | Apr. 7, 2022 | Honorable Renee Marie Bumb | Gimoti® (metoclopramide nasal spray) | 8334281 11,020,361 |
Otsuka Pharm. Co., Ltd. v. Mylan Labs. Ltd., 22-0464 (D. Del.) | Apr. 8, 2022 | Honorable Colm F. Connolly | Abilify Maintena® (aripiprazole extended-release injection) | 7,807,680 8,030,313 8,722,679 8,399,469 8,338,427 10,525,057 10,980,803 11,154,553 |
Otsuka Pharm. Co., Ltd. v. Mylan Labs. Ltd., 22-0032 (N.D.W.V.) | Apr. 8, 2022 | Honorable Thomas S. Kleeh | Abilify Maintena® (aripiprazole extended-release injection) | 7,807,680 8,030,313 8,722,679 8,399,469 8,338,427 10,525,057 10,980,803 11,154,553 |
Bayer Intellectual Property GmbH v. Changzhou Pharm. Factory, 22-2089 (D.N.J.) | Apr. 11, 2022 | Honorable Kevin McNulty | Xarelto® (rivaroxaban tablets) | 9,539,218 |
Avadel CNS Pharms., LLC v. Jazz Pharms., Inc., 22-0487 (D. Del.) | Apr. 14, 2022 | Honorable Maryellen Noreika | Xyrem® (sodium oxybate oral solution) | 10,758,488 10,813,885 10,959,956 10,966,931 11,077,079 11,147,782 |
Novartis Pharms. Corp. v. Dr. Reddy’s Labs., Inc., 22-0498 (D. Del.) | Apr. 19, 2022 | Honorable Richard G. Andrews | Entresto® (sacubitril / valsartan tablets) | 11,058,667 |
Arbor Pharms., LLC v. Amneal Pharms., LLC, 22-2323 (D.N.J.) | Apr. 21, 2022 | Honorable Karen W. Williams | Nymalize® (nimodipine oral solution) | 7,070,581 8,517,997 10,342,787 10,576,070 11,207,306 |
Otsuka Pharm. Co., Ltd. v. Teva Pharms. Inc., 22-0513 (D. Del.) | Apr. 22, 2022 | Honorable Richard G. Andrews | Jynarque® (tolvaptan tablets) | 8501730 10,905,694 |
BioMarin Pharm. Inc. v. Aurobindo Pharms. Ltd., 22-2345 (D.N.J.) | Apr., 22, 2022 | Honorable Michael A. Shipp | Kuvan® (sapropterin dihydrochloride tablets) | 7,566,462 7,566,714 7,612,073 7,727,987 8,003,126 8,067,416 RE43,797 8,318,745 9,433,624 |
Astellas US LLC v. GE Healthcare Inc., 22-0523 (D. Del.) | Apr. 25, 2022 | Honorable Colm F. Connolly | Lexiscan® (regadenoson intravenous solution) | 8106183 RE47,301 8,524,883 |
AstraZeneca AB v. Mylan Pharms. Inc., 22-0035 (N.D.W.V.) | Apr. 26, 2022 | Honorable Gina M. Groh | Symbicort® (budesonide / formoterol fumarate dehydrate inhalation aerosol) | 11,311,558 |
Alcon Inc. v. Somerset Therapeutics, LLC, 22- 0543 (D. Del) | Apr. 27, 2022 | Vacant Judgeship (2022) | Pataday® Once- Daily (olopatadine HCl ophthalmic solution) | 8,791,154 9,533,053 |
Journey Medical Corp. v. Padagis Israel Pharms. Ltd., 22-0587 (D. Del.) | May 2, 2022 | Honorable Colm F. Connolly | Zilxi® (minocycline topical foam) | 8,865,139 8,945,516 8,992,896 9,675,700 10,213,512 10,265,404 10,322,186 10,946,101 |
Otsuka Pharm. Co., Ltd. v. Sandoz Inc., 22- 0591 (D. Del) | May 2, 2022 | Honorable Leonard P. Stark | Rexulti® (brexpiprazole tablets) | 8,618,109 9,839,637 |
Gilead Sciences, Inc. v. Lupin Ltd., 22-0615 (D. Del.) | May 9, 2022 | Honorable MaryEllen Noreika | Biktarvy® (bictegravir sodium / tenofovir alafenamide fumarate / emtricitabine tablets) |
9,708,342 10,385,067 10,548,846 |
Bristol-Myers Squibb Co. v. Nanocopoeia, LLC, 22-1283 (D. Minn) | May 10, 2022 | Honorable Katherine M. Mendenez | Sprycel® (dasatinib tablets) | 7,491,725 8,680,103 |
Abraxis BioScience, LLC v. Jiangsu Hengrui Pharms. Co., Ltd., 22-2745 (D.N.J.) | May 11, 2022 | Honorable Freda L. Wolfson | Abraxane® (paclitaxel protein- bound particles for injectable suspension) | 7,820,788 |
Jazz Pharms. Ireland Ltd. v. Lupin Ltd., 22- 2773 (D.N.J.) | May 11, 2022 | Honorable Stanley R. Chesler | Xywav® (calcium oxybate / magnesium oxybate / potassium oxybate / sodium oxybate oral solution) | 11,253,494 |
Aragon Pharms., Inc. v. Lupin Ltd., 22-0637 (D. Del.) | May 13, 2022 | Hon. Colm F. Connolly | Erleada® (apalutamide tablets) | 9,481,663 |
Neurocrine Biosciences, Inc. v. Lupin Ltd., 22-0639 (D. Del.) | May 13, 2022 | Honorable MaryEllen Noreika | Ingrezza® (valbenazine tosylate capsules) | 8,039,627 8,357,697 10,065,952 10,844,058 10,851,103 10,851,104 10,857,137 10,857,148 10,874,648 10,906,902 10,906,903 10,912,771 10,919,892 10,940,141 10,952,997 10,993,941 11,026,931 11,026,939 11,040,029 |
Horizon Medicines LLC v. Apotex Inc., 22- 0640 (D. Del.) | May 13, 2022 | Honorable Christopher J. Burke | Pennsaid® (diclofenac sodium topical solution) | 9,066,913 |
Par Pharm., Inc. v. Cipla Ltd., 22-2814 (D.N.J.) | May 13, 2022 | Honorable Madeline C. Arleo | Vasostrict® (vasopressin injection) | 9,919,026 9,925,233 9,962,422 9,968,649 9,974,827 9,981,006 10,010,575 |
Aragon Pharms., Inc. v. Lupin Ltd., 22-2825 (D.N.J.) | May 13, 2022 | Hon. Julien Xavier Neals | Erleada® (apalutamide tablets) | 9,481,663 |
Celgene Corp. v. Oncogen Pharma (Malaysia) Sdn. Bhd., 22-2952 (D.N.J.) | May 20, 2022 | Honorable Susan D. Wigenton | Revlimid® (lenalidomide capsules) | 7,465,800 7,855,217 7,968,569 8,530,498 8,648,095 9,101,621 9,101,622 |
Aragon Pharms., Inc. v. Zydus Worldwide DMCC, 22-2964 (D.N.J.) | May 20, 2022 | Honorable Julien Xavier Neals | Erleada® (apalutamide tablets) | 9,481,663 9,884,054 10,052,314 10,702,508 10,849,888 |
Momenta Pharms., Inc. v. Mylan Pharms., Inc., 22-0750 (W.D. Pa.) | May 20, 2022 | Honorable Robert J. Colville | Glatopa® (glatiramer acetate injection) | 8,859,489 9.395,374 |
Aragon Pharms., Inc. v. Sandoz Inc., 22-0678 (D. Del.) | May 24, 2022 | Honorable Colm F. Connolly | Erleada® (apalutamide tablets) | 8,445,507 8,802,689 9,388,159 9,481,663 9,987,261 |
Aragon Pharms., Inc. v. Sandoz Inc., 22-3044 (D.N.J.) | May 24, 2022 | Honorable Julien Xavier Neals | Erleada® (apalutamide tablets) | 8,445,507 8,802,689 9,388,159 9,481,663 9,987,261 |
Aragon Pharms., Inc. v. Eugia Pharma Specialities Ltd. (A.K.A. Eugia Pharma Specialties Ltd.), 22- 0688 (D. Del.) | May 26, 2022 | Honorable Colm F. Connolly | Erleada® (apalutamide tablets) | 8,445,507 8,802,689 9,388,159 9,481,663 9,987,261 |
Aragon Pharms., Inc. v. Eugia Pharma Specialities Ltd. (A.K.A. Eugia Pharma Specialties Ltd.), 22- 0688 (D. Del.) | May 26, 2022 | Honorable Julien Xavier Neals | Erleada® (apalutamide tablets) | 8,445,507 8,802,689 9,388,159 9,481,663 9,987,261 |
Aragon Pharms., Inc. v. Hetero Labs Ltd. Unit V, 22-0696 (D. Del.) | May 27, 2022 | Honorable Colm F. Connolly | Erleada® (apalutamide tablets) | 8,445,507 9,481,663 9,884,054 10,052,314 10,702,508 10,849,888 |
Eagle Pharms., Inc. v. Accord Healthcare Inc., 22-0704 (D. Del.) | May 27, 2022 | Honorable Colm F. Connolly | Belrapzo® (bendamustine HCl injection) | 8,609,707 9,265,831 9,572,796 9,572,797 10,010,533 11,103,483 |
Aragon Pharms., Inc. v. Hetero Labs Ltd. Unit V, 22-3212 (D.N.J.) | May 27, 2022 | Hon. Julien Xavier Neals | Erleada® (apalutamide tablets) | 8,445,507 9,481,663 9,884,054 10,052,314 10,702,508 10,849,888 |
Ingenus Pharms., LLC v. Nexus Pharms., Inc., 22-2868 (N.D. Ill.) | June 1, 2022 | Honorable Mary M. Rowland | cyclophosphamide injection | 10,993,952 |
Galderma Labs., L.P. v. Apotex Inc., 22-0724 (D. Del.) | June 2, 2022 | Honorable Stephanos Bibas | Oracea® (doxycycline capsules) | 7,749,532 8,206,740 |
Novartis Pharms. Corp. v. Biocon Pharma Ltd., 22-0726 (D. Del.) | June 2, 2022 | Honorable Richard G. Andrews | Entresto® (sacubitril / valsartan tablets) | 11,058,667 |
Vertex Pharms. Inc. v. Aurobindo Pharma Ltd., 22 - 0728 (D. Del.) | June 2, 2022 | Honorable Richard G. Andrews | Kalydeco® (ivacaftor tablets) | 10,646,481 |
Avion Pharms., LLC v. Lupin Ltd., 22-0729 (D. Del.) | June 2, 2022 | Honorable Colm F. Connolly | Balcoltra® (levonorgestrel ethinyl estradiol / ferrous bisglycinate tablets) | 7,838,042 |
Novartis Pharms. Corp. v. Accord Healthcare Inc., 22- 0744 (D. Del.) | June 6, 2022 | Honorable MaryEllen Noreika | Rydapt® (midostaurin capsules) | 7,973,031 |
Pfizer Inc. v. MSN Labs. Private Ltd., 22- 0746 (D. Del.) | June 6, 2022 | Honorable Colm F. Connolly | Xeljanz® (tofacitinib oral solution) | RE41,783 |
Bristol-Myers Squibb Co. v. Biocon Pharma Ltd., 22-3505 (D.N.J.) | June 6, 2022 | Honorable Noel L. Hillman | Sprycel® (dasatinib tablets) | 7491725 8,680,103 |
Novartis Pharms. Corp. v. Accord Healthcare Inc., 22- 0431 (M.D.N.C.) | June 6, 2022 | Honorable William L. Osteen, Jr. | Rydapt® (midostaurin capsules) | 7,973,031 |
Eisai Co., Ltd. v. Aurobindo Pharma Ltd., 22-3610 (D.N.J.) | June 8, 2022 | Honorable Christine P. O'Hearn | Banzel® (rufinamide tablets) | 6,740,669 |
Mylan Pharms. Inc. v. Bausch Health Ireland Ltd., IPR2022-01102 (PTAB) | June 10, 2022 | N/A | Trulance® (plecanatide tablets) | 9,610,321 |
Mylan Pharms. Inc. v. Bausch Health Ireland Ltd., IPR2022-01103 (PTAB) | June 10, 2022 | N/A | Trulance® (plecanatide tablets) | 9,616,097 |
Mylan Pharms. Inc. v. Bausch Health Ireland Ltd., IPR2022-01104 (PTAB) | June 10, 2022 | N/A | Trulance® (plecanatide tablets) | 9,919,024 |
Mylan Pharms. Inc. v. Bausch Health Ireland Ltd., IPR2022-01105 (PTAB) | June 10, 2022 | N/A | Trulance® (plecanatide tablets) | 9,925,231 |
Bristol-Myers Squibb Co. v. Accord Healthcare Inc., 22- 3743 (D.N.J.) | June 13, 2022 | Honorable Renee Marie Bumb | Sprycel® (dasatinib tablets) | 7,491,725 8,680,103 |
Celgene Corp. v. Qilu Pharm. Co., Ltd., 22- 3753 (D.N.J.) | June 13, 2022 | Honorable Susan D. Wigenton | Revlimid® (lenalidomide capsules) | 7,465,800 7,855,217 |
Amgen Inc. v. Apotex Inc., 22-3827 (D.N.J.) | June 14, 2022 | Honorable Michael A. Shipp | Otezla® (apremilast tablets) | 7,427,638 9,872,854 10,092,541 |
Astellas Pharma Inc. v. Sawai Pharm. Co., Ltd., 22-0818 (D. Del.) | June 17, 2022 | Honorable Joseph F. Bataillon | Myrbetriq® (mirabegron extended-release tablets) | 6,346,532 7,342,117 7,982,049 8,835,474 RE44,872 10,842,780 |
Scilex Pharms. Inc. v. Aveva Drug Delivery Systems, Inc., 22-61192 (S.D. Fla.) | June 22, 2022 | Honorable William P. Dimitrouleas | ZTlido® (lidocaine topical system) | 9,283,174 9,925,264 9,931,403 |
Gilead Sciences, Inc. v. Natco Pharma Ltd., 22- 0852 (D. Del.) | June 23, 2022 | Honorable Richard G. Andrews | Zydelig® (idelalisib tablets) | RE44,599 RE44,638 8,865,730 9,469,643 10,730,879 |
Chemo Research SL v. Encube Ethicals Private, Ltd., 22-0854 (D. Del.) | June 24, 2022 | Honorable Colm F. Connolly | Nuvessa® (metronidazole vaginal gel) | 7,893,097 8,658,678 8,877,792 8,946,276 9,198,858 10,238,634 10,596,155 |
Novo Nordisk Inc. v. Orbicular Pharm. Technologies Pvt. Ltd., 22-0856 (D. Del.) | June 24, 2022 | Honorable Colm F. Connolly | Saxenda® (liraglutide recombinant solution injection) | 7,762,994 8,114,833 8,579,869 8,684,969 8,920,383 9,108,002 9,132,239 9,457,154 9,616,180 9,687,611 9,775,953 9,861,757 10,220,155 10,357,616 10,376,652 11,097,063 11,311,679 RE46,363 |
Bausch Health Ireland Ltd. v. Padagis Israel Pharms. Ltd., 22-4248 (D.N.J.) |
June 24, 2022 | Honorable Madeline Cox Arleo | Arazlo® (tazarotene lotion) | 11,311,482 |
Bristol-Myers Squibb Co. v. Xspray Pharma AB, 22-4328 (D.N.J.) | June 29, 2022 | Hon. Renee Marie Bumb | Sprycel® (dasatinib tablets) | 7,491,725 8,680,103 |
Bausch & Lomb Inc. v. Gland Pharma Ltd., 22-4345 (D.N.J.) | June 30, 2022 | Honorable Michael A. Shipp | Vyzulta® (latanoprostene bunod ophthalmic solution) | 7,273,946 7,629,345 7,910,767 8,058,467 |
GENERICally Speaking Hatch Waxman Bulletin
GENERICally Speaking Hatch Waxman Bulletin
READ MORE Related Publications
Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.